(S)-N-(3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl)-5-methyl-3-(2,4,5-trifluorophenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine-1-carboxamide → (S)-3-(3,4-difluorophenyl)-N-(3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl)-5-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine-1-carboxamide

참여 물질

반응 단계

Compound 42 was prepared according to the procedure described for the synthesis of compound 37 by replacing intermediate 19 with intermediate 15. 1H NMR (CDCl3) δ 7.89 (d, J=9.4 Hz, 1H), 7.49-7.55 (m, 1H), 7.39-7.43 (m, 1H), 7.19-7.25 (m, 1H), 5.80 (br, 1H), 4.11 (d, J=9.4 Hz, 1H), 3.57 (s, 2H), 3.16-3.20 (m, 2H), 2.84 (d, J=4.8 Hz, 3H), 2.73 (t, J=5.8 Hz, 2H), 2.53 (s, 3H), 1.08 (s, 9H). LCMS (+ESI) m/z=420 [M+H]+.

출처 및 근거